FDA approves Arcutis Biotherapeutics’ ZORYVE for pediatric and adult atopic dermatitis
In a significant development for the treatment of atopic dermatitis (AD), Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the U.S. Food and Drug Administration (FDA) approval of ZORYVE (roflumilast) cream, 0.15%, for patients aged six years and older. This approval marks a pivotal advancement in immuno-dermatology, offering a steroid-free, once-daily cream that targets mild to moderate […]